Streetbeat News

Analyst Ratings

KPTI

HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on Karyopharm Therapeutics (NASDAQ:KPTI) and maintained a $10 price target.

Portfolio Pulse from richadhand@benzinga.com

July 26, 2023 | 10:12 am

CCK

Barclays analyst Michael Leithead has maintained an Overweight rating on Crown Holdings (NYSE:CCK) and raised the price target from $95 to $110.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 26, 2023 | 10:11 am

GOSS

HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Gossamer Bio (NASDAQ:GOSS) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

July 26, 2023 | 10:10 am

TARS

HC Wainwright & Co. analyst Oren Livnat maintains a Buy rating on Tarsus Pharmaceuticals (NASDAQ:TARS) and raises the price target from $44 to $50.

Portfolio Pulse from richadhand@benzinga.com

July 26, 2023 | 10:10 am

SHW

Barclays analyst Michael Leithead maintains an Equal-Weight rating on Sherwin-Williams (NYSE:SHW) and raises the price target from $240 to $285.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 26, 2023 | 10:09 am

BIIB

Needham analyst Ami Fadia maintains a Buy rating on Biogen (NASDAQ:BIIB) and raises the price target from $320 to $323.

Portfolio Pulse from richadhand@benzinga.com

July 26, 2023 | 10:08 am

ALK

Barclays analyst Brandon Oglenski maintains an Overweight rating on Alaska Air Gr (NYSE:ALK) but has lowered the price target from $66 to $62.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 26, 2023 | 10:08 am

JAMF

Needham analyst Joshua Reilly has reiterated a 'Buy' rating on Jamf Holding (NASDAQ:JAMF) and maintained a price target of $35.

Portfolio Pulse from richadhand@benzinga.com

July 26, 2023 | 10:07 am

TRU

Barclays analyst Manav Patnaik maintains an Equal-Weight rating on TransUnion (NYSE:TRU) and raises the price target from $67 to $80.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 26, 2023 | 10:06 am

GPI

Group 1 Automotive (NYSE:GPI) reported Q2 earnings of $11.73 per share, beating the analyst consensus estimate of $11.08 by 5.87%. However, this is a 2.25% decrease from the same period last year. The company also reported quarterly sales of $4.56 billion, beating the analyst consensus estimate of $4.36 billion by 4.59%, and marking a 10.01% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2023 | 10:06 am